Thomas Delong
NIH Rank #1528
- Rising Star
- Program Leader
- R01 Holder
- Translational
- Top 10% Funded
- Early Career
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 9753886Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
FY2026 award categories
- Pharmacology
NIH Funding · FY2026
Linked Award Amount
$3M
Full award amounts, FY2026
Award Records
3
Records listing this PI
Award-Linked Rank
#1,528
By linked amount among FY2026 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2026 award records by amount
NIH award records listing Thomas Delong as a PI. Multi-PI records show the full award amount for context.
- 4U01DK143495-02U01The Role of Granular Acidification in the Pathogenesis of Type 1 Diabetes$2Maward amount
- 5R01DK119529-09R01Characterize the Landscape and Origin of Hybrid Peptides in Beta Cells$529.6Kaward amount
- 1R21AI196871-01R21Species-Specific Regulation of Autoantigen Processing: A Humanized Mouse Model of Cathepsin D in Type 1 Diabetes$429Kaward amount
Award organization
Organizations that administered FY2026 awards listing Thomas Delong as a PI.
FY2026 award administered by University of Colorado (CO).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardUniversity of Colorado
- 2024$500K Cumulative Funding
- 2025$1M Cumulative Funding
- 2025$2M Cumulative Funding
- 2025Entered Top 50% NationallyRanked #8039
- 2025R01 Grant Holder
- 2025Program/Center Grant Leader
- 2026$5M Cumulative Funding
- 2026Entered Top 25% NationallyRanked #1528
- 2026Entered Top 10% NationallyRanked #1528